Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease

Claire Painchart,Séverine Brabant,Nicolas Duveau,Maria Nachury,Pierre Desreumaux,Julien Branche,Romain Gerard,Clémentine Lauriot Dit Prevost,Pauline Wils,Thomas Lambin,Medina Boualit,Myriam Labalette,Benjamin Pariente

Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease

2019

Claire Painchart
Séverine Brabant
Nicolas Duveau
Maria Nachury
Pierre Desreumaux
Julien Branche
Romain Gerard
Clémentine Lauriot Dit Prevost
Pauline Wils
Thomas Lambin
Medina Boualit
Myriam Labalette
Benjamin Pariente

Introduction The aim of this study was to evaluate the association between serum ustekinumab (UST) trough levels and response to induction and maintenance UST treatment in refractory Crohn’s Disease (CD) patients.

Keywords:

Ustekinumab
Diabetes mellitus
Internal medicine
Endocrinology
Refractory
Medicine
Disease
Crohn's disease
Prospective cohort study
Hepatology
Trough Concentration
Gastroenterology
Cohort

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations